Carole Ho, M.D., serves as the Chief Medical Officer at Denali Therapeutics Inc., a biopharmaceutical company focused on developing transformative therapies for neurodegenerative diseases. Dr. Ho brings a wealth of experience and expertise to her role, having spent over two decades in the biopharmaceutical industry. Prior to joining Denali, she held leadership positions at several prominent companies, including Genentech, where she served as the Senior Vice President of Clinical Development. Her work at Genentech was instrumental in advancing multiple oncology and immunology programs through clinical development and regulatory approval. Dr. Ho's academic background is equally impressive. She earned her medical degree from the University of Pennsylvania School of Medicine and completed her residency in internal medicine at the Hospital of the University of Pennsylvania. Her commitment to advancing medical science is evident in her numerous publications and presentations at international conferences. Throughout her career, Dr. Ho has been recognized for her contributions to the field, receiving several awards and accolades for her leadership and innovation in clinical development. As Chief Medical Officer at Denali Therapeutics, Dr. Ho plays a pivotal role in overseeing the company's clinical development strategy and execution. Her leadership is crucial in guiding Denali's pipeline of novel therapies aimed at addressing the underlying causes of neurodegenerative diseases. Under her guidance, the company has made significant strides in advancing its clinical programs, with several candidates now in various stages of clinical trials. Dr. Ho's expertise and strategic vision continue to drive Denali's mission to bring life-changing treatments to patients suffering from debilitating neurological conditions.